[go: up one dir, main page]

WO1999060021A3 - Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system - Google Patents

Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system Download PDF

Info

Publication number
WO1999060021A3
WO1999060021A3 PCT/US1999/010953 US9910953W WO9960021A3 WO 1999060021 A3 WO1999060021 A3 WO 1999060021A3 US 9910953 W US9910953 W US 9910953W WO 9960021 A3 WO9960021 A3 WO 9960021A3
Authority
WO
WIPO (PCT)
Prior art keywords
nervous system
cells
activated
antigen
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/010953
Other languages
French (fr)
Other versions
WO1999060021A2 (en
Inventor
Michal Eisenbach-Schwartz
Irun R Cohen
Pierre Beserman
Alon Mosonego
Gila Moalem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL12455098A external-priority patent/IL124550A0/en
Priority claimed from PCT/US1998/014715 external-priority patent/WO1999034827A1/en
Priority claimed from US09/218,277 external-priority patent/US20030108528A1/en
Priority to EP99923190A priority Critical patent/EP1080110A2/en
Priority to IL13952599A priority patent/IL139525A0/en
Priority to AU40017/99A priority patent/AU768763B2/en
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Priority to JP2000549639A priority patent/JP2003532618A/en
Priority to CA002328612A priority patent/CA2328612A1/en
Publication of WO1999060021A2 publication Critical patent/WO1999060021A2/en
Publication of WO1999060021A3 publication Critical patent/WO1999060021A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Compositions and methods are provided for treating injury to or disease of the central or peripheral nervous system. In one embodiment, treatment is effected using activated T cells that recognize an antigen of the nervous system or a peptide derived therefrom or a derivative thereof to promote nerve regeneration or to prevent or inhibit neuronal degeneration within the nervous system. Treatment involves administering an NS-specific antigen or peptide derived therefrom or a derivative thereof, or a nucleotide sequence encoding said antigen or peptide, to promote nerve regeneration or to prevent or inhibit neuronal degeneration in the nervous system, either the central nervous system or the peripheral nervous system. The NS-specific activated T cells can be administered alone or in combination with NS-specific antigen or peptide derived therefrom or a derivative thereof or a nucleotide sequence encoding said antigen or peptide, or any combination thereof.
PCT/US1999/010953 1998-05-19 1999-05-19 Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system Ceased WO1999060021A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002328612A CA2328612A1 (en) 1998-05-19 1999-05-19 Activated t cells, nervous system-specific antigens and their uses
JP2000549639A JP2003532618A (en) 1998-05-19 1999-05-19 Cells, nervous system-specific antigens and their uses
EP99923190A EP1080110A2 (en) 1998-05-19 1999-05-19 Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system
IL13952599A IL139525A0 (en) 1998-05-19 1999-05-19 Activated t cells nervous system-specific antigens and their uses
AU40017/99A AU768763B2 (en) 1998-05-19 1999-05-19 Activated T cells, nervous system-specific antigens and their uses

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IL124550 1998-05-19
IL12455098A IL124550A0 (en) 1997-07-21 1998-05-19 Compositions comprising activated t-cells or t-cell activating agents and their use
PCT/US1998/014715 WO1999034827A1 (en) 1998-07-21 1998-07-21 Activated t-cells and their uses
USPCT/US98/14715 1998-07-21
US09/218,277 1998-12-22
US09/218,277 US20030108528A1 (en) 1998-05-19 1998-12-22 Activated t-cells, nervous system-specific antigens and their uses

Publications (2)

Publication Number Publication Date
WO1999060021A2 WO1999060021A2 (en) 1999-11-25
WO1999060021A3 true WO1999060021A3 (en) 2000-06-15

Family

ID=27271868

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/010953 Ceased WO1999060021A2 (en) 1998-05-19 1999-05-19 Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system

Country Status (4)

Country Link
EP (1) EP1080110A2 (en)
JP (1) JP2003532618A (en)
CA (1) CA2328612A1 (en)
WO (1) WO1999060021A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1072897A (en) 1995-12-12 1997-07-03 Karolinska Innovations Ab Peptide binding the klvff-sequence of amyloid beta
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US7060670B1 (en) 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
PE20020574A1 (en) 2000-12-06 2002-07-02 Wyeth Corp HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US7351686B2 (en) 2001-12-06 2008-04-01 Yeda Research And Development Co. Ltd. Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
PE20050627A1 (en) 2003-05-30 2005-08-10 Wyeth Corp HUMANIZED ANTIBODIES THAT RECOGNIZE THE BETA AMYLOID PEPTIDE
JP2008523815A (en) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド Humanized amyloid beta antibody for use in improving cognition
EP1838854B1 (en) 2004-12-15 2012-10-31 Janssen Alzheimer Immunotherapy Antibodies that recognize Beta Amyloid Peptide
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PT2182983E (en) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US20150238582A1 (en) 2012-09-10 2015-08-27 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Individualized immunomodulation therapy for neurodegenerative disorders, cns injury and age-related dementia

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001746A1 (en) * 1989-08-09 1991-02-21 The Children's Medical Center Corporation Thy-1 receptor and its use for regenerating nerve cell processes
WO1993021222A1 (en) * 1992-04-09 1993-10-28 Autoimmune, Inc. Suppression of t-cell proliferation using peptide fragments of myelin basic protein
WO1995022344A1 (en) * 1994-02-21 1995-08-24 Mcgill University Therapeutic use of myelin-associated glycoprotein (mag)
WO1995027500A1 (en) * 1994-04-08 1995-10-19 Brigham And Women's Hospital TREATMENT OF AUTOIMMUNE DISEASE USING ORAL TOLERIZATION AND/OR Th2-ENHANCING CYTOKINES
WO1996012737A2 (en) * 1994-10-25 1996-05-02 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
WO1997001352A1 (en) * 1995-06-27 1997-01-16 Research Foundation Of Cuny, Hunter College Compositions and methods using myelin-associated glycoprotein (mag) and inhibitors thereof
WO1997009885A1 (en) * 1995-09-15 1997-03-20 Yeda Research And Development Co., Ltd. Compositions and methods of use of mononuclear phagocytes to promote axonal regeneration
WO1997014427A1 (en) * 1995-10-17 1997-04-24 A+ Science Invest Ab USE OF PROTEIN S-100b IN MEDICINES AND MEDICINES CONTAINING THE PROTEIN S-100b
WO1997035879A1 (en) * 1996-03-28 1997-10-02 Immulogic Pharmaceutical Corporation Myelin oligodendrocyte glycoprotein peptides and uses thereof
WO1999012966A1 (en) * 1997-09-11 1999-03-18 Astra Aktiebolag Peptides comprising an immunodominant sequence derived from human myelin oligodendrocyte glycoprotein
WO1999053945A1 (en) * 1998-04-16 1999-10-28 Samuel David Neuron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001746A1 (en) * 1989-08-09 1991-02-21 The Children's Medical Center Corporation Thy-1 receptor and its use for regenerating nerve cell processes
WO1993021222A1 (en) * 1992-04-09 1993-10-28 Autoimmune, Inc. Suppression of t-cell proliferation using peptide fragments of myelin basic protein
WO1995022344A1 (en) * 1994-02-21 1995-08-24 Mcgill University Therapeutic use of myelin-associated glycoprotein (mag)
WO1995027500A1 (en) * 1994-04-08 1995-10-19 Brigham And Women's Hospital TREATMENT OF AUTOIMMUNE DISEASE USING ORAL TOLERIZATION AND/OR Th2-ENHANCING CYTOKINES
WO1996012737A2 (en) * 1994-10-25 1996-05-02 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
WO1997001352A1 (en) * 1995-06-27 1997-01-16 Research Foundation Of Cuny, Hunter College Compositions and methods using myelin-associated glycoprotein (mag) and inhibitors thereof
WO1997009885A1 (en) * 1995-09-15 1997-03-20 Yeda Research And Development Co., Ltd. Compositions and methods of use of mononuclear phagocytes to promote axonal regeneration
WO1997014427A1 (en) * 1995-10-17 1997-04-24 A+ Science Invest Ab USE OF PROTEIN S-100b IN MEDICINES AND MEDICINES CONTAINING THE PROTEIN S-100b
WO1997035879A1 (en) * 1996-03-28 1997-10-02 Immulogic Pharmaceutical Corporation Myelin oligodendrocyte glycoprotein peptides and uses thereof
WO1999012966A1 (en) * 1997-09-11 1999-03-18 Astra Aktiebolag Peptides comprising an immunodominant sequence derived from human myelin oligodendrocyte glycoprotein
WO1999053945A1 (en) * 1998-04-16 1999-10-28 Samuel David Neuron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration

Also Published As

Publication number Publication date
WO1999060021A2 (en) 1999-11-25
JP2003532618A (en) 2003-11-05
CA2328612A1 (en) 1999-11-25
EP1080110A2 (en) 2001-03-07

Similar Documents

Publication Publication Date Title
WO1999060021A3 (en) Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system
WO2001052878A8 (en) The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy
WO2001093893A3 (en) The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy
MXPA02001587A (en) Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue.
IL225192A (en) Combination of dextromethorphan and quinidine for use in the treatment of mental illness, neuropathic pain or brain injury
WO1995017154A3 (en) Use of thalidomide for treating neurocognitive disorders
WO2004110360A3 (en) Proteoglycan degrading mutants for treatment of cns
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
WO2004030524A3 (en) Treatment of autism and similar disorders
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
WO1999056666A8 (en) The treatment of sexual dysfunction in certain patient groups
AU5659798A (en) Therapeutic composition comprising the kal protein and use of the kal protein for the treatment of retinal, renal, neuronal and neural injury
Tamminen et al. A double-blind parallel study to compare fluoxetine with doxepin in the treatment of major depressive disorder.
WO2001082954A3 (en) Ceruloplasmin and uses thereof in neurodegenerative related conditions
Morimoto et al. The effect of indomethacin stupe for post-herpetic neuralgia—particularly in comparison with chloroform-aspirin solution
RU93050675A (en) METHOD FOR CORRECTION OF PSYCHOPHYSIOLOGICAL STATE OF HUMAN
WO2005094497A3 (en) Systemic delivery of therapeutics to central nervous system
BR0317772A (en) Method of treating a behavioral disorder, use of a compound, and therapeutic agent for a behavioral disorder
AU6258798A (en) Facilitation of repair of neural injury with cm101/gbs toxin
WO2000001440A3 (en) Methods for treating neurological injuries and disorders
GB9930419D0 (en) Replication incompetent herpes virus vectors
Owen et al. Successful treatment of severe psoriasis with ustekinumab in a 13-year old girl
WO2001034178A3 (en) Methods and compositions for treatment of traumatic brain injury
WO2006031314A3 (en) Use of tyrphostins to stimulate neurite outgrowth
WO2001072955A3 (en) Regulation of human nedd1-related protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2328612

Country of ref document: CA

Ref country code: CA

Ref document number: 2328612

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 139525

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/011385

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: KR

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 549639

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 40017/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999923190

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999923190

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 40017/99

Country of ref document: AU